BIOMOLECULAR LIFE HOLDINGS, INC. 8-K, filed Jul 8, 2008: Current report filing
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 5, 2008
VIRAL
GENETICS, INC.
(Exact
name of registrant as specified in its charter)
000-26875
(Commission
File No.)
|
Delaware
|
33-0814123
|
|||
|
(State or other
jurisdiction of
incorporation or
organization)
|
(IRS Employer
Identification No.)
|
1321
Mountain View Circle, Azusa, CA 91702
(Address
of principal executive offices)
(626)
334-5310
(Registrant’s
telephone number)
Not
Applicable
(Former
address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see General Instruction A.2. below):
| □ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| □ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| □ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| □ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240. 13e-4(c))
|
Item
3.02 Unregistered Sales of Equity Securities
On March
5, 2008, Best Investments, Inc. (“Best”), an affiliate of the registrant’s
President, Haig Keledjian, entered into a Debt Restructuring Agreement with the
registrant whereby the registrant and Best agreed to restructure $1,508,302.00
in outstanding indebtedness owed by the registrant to Best. The
original indebtedness matured on March 29, 2008.
The Debt
Restructuring Agreement converted the existing indebtedness to a revolving line
of credit which is secured by substantially all of the assets of the
registrant. The revolving line of credit matures June 30, 2013, bears
interest at the rate of 5% per annum, payable at the maturity
date. The obligations under the revolving line of credit may be
prepaid at any time and may be exchanged for common stock and a
warrant. The conversion price is equal to the volume weighted closing
price of the registrant’s common stock for the 20 trading days preceding notice
of conversion by Best to the registrant. For each share of stock
issued for conversion of obligations, Best will receive a warrant to purchase a
share of common stock for 150% of the price for which obligations under the
revolving line of credit were converted. The warrant expires five years from the
date of issuance.
The
amount Best agreed to lend the registrant under the revolving line of credit was
not limited. The obligations of the registrant under the revolving line of
credit are guaranteed by its subsidiary, Viral Genetics, Inc., a California
corporation.
Item
9.01. Financial Statements and Exhibits.
Exhibits
Copies of
the following documents are included as exhibits to this report pursuant to Item
601 of Regulation S-K.
|
Number
|
Description
|
|
|
10.1
|
Debt
Restructuring Agreement
|
|
|
10.2
|
Security
Agreement
|
|
|
10.3
|
Subsidiary
Guarantee
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| VIRAL GENETICS, INC. | |||
|
Dated: July 8,
2008
|
By: | /s/ Haig Keledjian | |
| Haig Keledjian, President | |||
2